Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (OR...
Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular diseases discovered and developed by Valo using the Opal Computational ...
Paratek's successful commercialization platform to advance novel therapies developed organically and through acquisitions Paratek adds 'final-mile' capa...
The healthcare landscape in Latin America is currently a worldwide priority. Factors such as increasing awareness of precision medicine, the growing preval...
Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic r...
Located in Sapporo, Japan, Hokkaido University Hospital stands as one of the most prominent medical institutions in the country. Affiliated with Hokkaido U...
“While shocking, this move by Johnson & Johnson is unfortunately not surprising – we demand that the company halt its profiteering tactics ...
The primary objective is to evaluate VISTA as a biomarker to guide patient selection and treatment optimization for VISTA-targeted therapies where no stand...
Mayo Clinic and GE HealthCare announce a strategic healthcare collaboration for research and product development programs aimed to transform the experience...
Genetic Technologies Limited (GTG), a pioneering global leader in genomics-based tests focused on health, wellness, and the battle against serious diseases...
SomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types. In a new paper published in Nature's Scientific Repo...
Second commercialized product strengthens Clover’s leading respiratory vaccine franchise and financial profile-- Clover Biopharmaceutica...
In an exclusive interview with Yoav Blat, BARIKS' Representative in North America, we explore the technology behind this chamber and its potential to revol...
Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predict...
© 2025 Biopharma Boardroom. All Rights Reserved.
